p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability

[1]  P. Sung,et al.  The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication , 2020, Nature Reviews Molecular Cell Biology.

[2]  S. Zha,et al.  The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection. , 2018, Molecular cell.

[3]  R. Weichselbaum,et al.  BCL3 expression promotes resistance to alkylating chemotherapy in gliomas , 2018, Science Translational Medicine.

[4]  M. Christie,et al.  Loss of NF‐&kgr;B1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT‐1‐Dependent Manner , 2018, Immunity.

[5]  N. Perkins,et al.  NFKB1: a suppressor of inflammation, ageing and cancer , 2016, The FEBS journal.

[6]  Krishna R. Kalari,et al.  A cell cycle-dependent BRCA1–UHRF1 cascade regulates DNA double-strand break repair pathway choice , 2016, Nature Communications.

[7]  S. Fields,et al.  Functional Analysis of BARD1 Missense Variants in Homology‐Directed Repair of DNA Double Strand Breaks , 2015, Human mutation.

[8]  A. Moore,et al.  Corrigendum: NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma , 2015, Nature Communications.

[9]  R. Greenberg,et al.  Deciphering the BRCA1 Tumor Suppressor Network* , 2015, The Journal of Biological Chemistry.

[10]  A. Ciechanover,et al.  KPC1-Mediated Ubiquitination and Proteasomal Processing of NF-κB1 p105 to p50 Restricts Tumor Growth , 2015, Cell.

[11]  T. Ohta,et al.  Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage. , 2015, Cancer research.

[12]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Weichselbaum,et al.  S-phase-dependent p50/NF-кB1 phosphorylation in response to ATR and replication stress acts to maintain genomic stability , 2015, Cell cycle.

[14]  L. Jensen,et al.  Cyclebase 3.0: a multi-organism database on cell-cycle regulation and phenotypes , 2014, Nucleic Acids Res..

[15]  R. Weichselbaum,et al.  Loss of Nfkb1 leads to early onset aging , 2014, Aging.

[16]  Laura C. Greaves,et al.  Chronic inflammation induces telomere dysfunction and accelerates ageing in mice , 2014, Nature Communications.

[17]  Megan E. McNerney,et al.  Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor , 2014, Oncogene.

[18]  Mo Li,et al.  Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. , 2013, Cancer cell.

[19]  H. Hakonarson,et al.  Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. , 2013, Carcinogenesis.

[20]  O. Delattre,et al.  PHOX2B Immunolabeling: A Novel Tool for the Diagnosis of Undifferentiated Neuroblastomas Among Childhood Small Round Blue-cell Tumors , 2012, The American journal of surgical pathology.

[21]  S. Ghosh,et al.  NF-κB, the first quarter-century: remarkable progress and outstanding questions. , 2012, Genes & development.

[22]  N. Perkins,et al.  The diverse and complex roles of NF-κB subunits in cancer , 2012, Nature Reviews Cancer.

[23]  R. Weichselbaum,et al.  p50 (NF-κB1) is an effector protein in the cytotoxic response to DNA methylation damage. , 2011, Molecular cell.

[24]  T. Hothorn,et al.  BARD1 Expression Predicts Outcome in Colon Cancer , 2011, Clinical Cancer Research.

[25]  A. Singh,et al.  p65 Negatively Regulates Transcription of the Cyclin E Gene* , 2010, The Journal of Biological Chemistry.

[26]  Willy Lissens,et al.  Cancer predisposing missense and protein truncating BARD1 mutations in non‐BRCA1 or BRCA2 breast cancer families , 2010, Human mutation.

[27]  Nazneen Rahman,et al.  Common variations in BARD1 influence susceptibility to high-risk neuroblastoma , 2009, Nature Genetics.

[28]  D. Lane,et al.  Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53* , 2009, Journal of Biological Chemistry.

[29]  Katia Basso,et al.  The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression , 2008, Proceedings of the National Academy of Sciences.

[30]  S. Ghosh,et al.  Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms. , 2008, Genes & development.

[31]  O. Fernandez-Capetillo,et al.  ATR signaling can drive cells into senescence in the absence of DNA breaks. , 2008, Genes & development.

[32]  Thomas Ludwig,et al.  Structural Requirements for the BARD1 Tumor Suppressor in Chromosomal Stability and Homology-directed DNA Repair* , 2007, Journal of Biological Chemistry.

[33]  P. Brzovic,et al.  E2–BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages , 2007, Nature Structural &Molecular Biology.

[34]  A. Varma,et al.  Crystal structure of the BARD1 BRCT domains. , 2007, Biochemistry.

[35]  A. Kumagai,et al.  TopBP1 Activates the ATR-ATRIP Complex , 2006, Cell.

[36]  R. Tibbetts,et al.  Molecular Linkage Between the Kinase ATM and NF-κB Signaling in Response to Genotoxic Stimuli , 2006, Science.

[37]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[38]  N. Lakin,et al.  Recruitment of the Cell Cycle Checkpoint Kinase ATR to Chromatin during S-phase* , 2004, Journal of Biological Chemistry.

[39]  Junjie Chen,et al.  Phosphopeptide Binding Specificities of BRCA1 COOH-terminal (BRCT) Domains* , 2003, Journal of Biological Chemistry.

[40]  Muyang Li,et al.  Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2 , 2003, Science.

[41]  R. Ricciardi,et al.  Phosphorylation of Serine 337 of NF-κB p50 Is Critical for DNA Binding* , 2003, Journal of Biological Chemistry.

[42]  Michael B Yaffe,et al.  BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting , 2003, Science.

[43]  Georges Mer,et al.  The BRCT Domain Is a Phospho-Protein Binding Domain , 2003, Science.

[44]  Jonathan D. Licht,et al.  BRCA1 Augments Transcription by the NF-κB Transcription Factor by Binding to the Rel Domain of the p65/RelA Subunit* , 2003, Journal of Biological Chemistry.

[45]  S. Gerondakis,et al.  NF-κB1 Can Inhibit v-Abl-Induced Lymphoid Transformation by Functioning as a Negative Regulator of Cyclin D1 Expression , 2002, Molecular and Cellular Biology.

[46]  L. Iyer,et al.  Determination of Substrate Motifs for Human Chk1 and hCds1/Chk2 by the Oriented Peptide Library Approach* , 2002, The Journal of Biological Chemistry.

[47]  T. Ohta,et al.  The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation* , 2001, The Journal of Biological Chemistry.

[48]  C. Scheidereit,et al.  Shared Pathways of IκB Kinase-Induced SCFβTrCP-Mediated Ubiquitination and Degradation for the NF-κB Precursor p105 and IκBα , 2001, Molecular and Cellular Biology.

[49]  K. Cimprich,et al.  Xenopus ATR is a replication-dependent chromatin-binding protein required for the DNA replication checkpoint , 2000, Current Biology.

[50]  W. Brownell,et al.  Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. , 2000, Genes & development.

[51]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[52]  B. Rayet,et al.  Aberrant rel/nfkb genes and activity in human cancer , 1999, Oncogene.

[53]  S. Reed,et al.  Deregulated cyclin E induces chromosome instability , 1999, Nature.

[54]  C. Scheidereit,et al.  The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators , 1999, Oncogene.

[55]  F. Couch,et al.  Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. , 1998, Molecular cell.

[56]  W. Greene,et al.  Cotranslational Biogenesis of NF-κB p50 by the 26S Proteasome , 1998, Cell.

[57]  B. Trask,et al.  Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. , 1998, Human molecular genetics.

[58]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[59]  A. Israël,et al.  Cytoplasmic retention, DNA binding and processing of the NF‐kappa B p50 precursor are controlled by a small region in its C‐terminus. , 1991, The EMBO journal.

[60]  S. Reed,et al.  Cyclin E Deregulation and Genomic Instability. , 2017, Advances in experimental medicine and biology.

[61]  N. Perkins,et al.  NF-k B is a critical mediator of BRCA 1-induced chemoresistance , 2014 .

[62]  Alexander Hoffmann,et al.  A single NFκB system for both canonical and non-canonical signaling , 2011, Cell Research.

[63]  O. Olopade,et al.  Stem Cells , Tissue Engineering and Hematopoietic Elements Wnt /-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome , 2010 .

[64]  T. Glover,et al.  DNA polymerase α inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes , 2004, Human Genetics.

[65]  Judy H. Cho,et al.  Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. , 2004, Human molecular genetics.

[66]  R. Ricciardi,et al.  Phosphorylation of serine 337 of NF-kappaB p50 is critical for DNA binding. , 2003, The Journal of biological chemistry.

[67]  C. Scheidereit,et al.  Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha. , 2001, Molecular and cellular biology.

[68]  W. Greene,et al.  Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome. , 1998, Cell.